CRS 2025 Annual Meeting & Exposition Pre-meeting Workshop: Recent Advances in Oral Peptide Delivery – From Molecule to Market
Philadelphia, PA 19107, United States | 14 July 2025Join Quotient Sciences along with industry leaders to hear latest insight in oral peptide development and clinical testing.
Systemic delivery of peptides by the oral route is now a reality with multiple products on the market and many more in development. Attendees will learn of the latest advances in oral peptide delivery and its future directions from world leading academics and industry leaders who have successfully taken oral peptide products from preclinical development to translation into the clinic and market launch. Topics covered include fundamental mechanisms, peptide engineering, oral peptide biopharmaceutics, novel drug delivery systems and their clinical development. Insights and learnings will be shared on how to navigate the unique challenges oral peptide programs present and future directions of the field.
Goals and Objectives
• Learn the latest developments in our understanding of oral peptide biopharmaceutics
• Hear the latest progress on the clinical development of oral products from industry leaders
• Share insights and learnings in managing the transition from preclinical to clinical development of oral peptide products
Chairs & Company Sponsors
- Andy Lewis, Chief Scientific Officer, Quotient Sciences
- Stephen Buckley, Vice President, Drug Product Research, Novo Nordisk
- David Brayden, Professor of Advanced Drug Delivery, University College Dublin
| Date | Location |
|---|---|
| Monday, July 14th, 2025 Time: 8:00 AM - 4:30 PM | Pennsylvania Convention Center 1101 Arch Street Philadelphia, PA 19107 |
*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.
Want to learn more about Quotient Sciences and our work with oral peptides? Check out additional resources here:
Learn how through our clinical pharmacology services, we investigated tablet erosion and the pharmacokinetics of
oral semaglutide administered with 2 different water volumes and evaluated the relationships between these parameters.Whitepaper - How to Optimize CMC and Clinical Strategies for Injectable & Oral Peptide Drugs
The exquisite specificity/selectivity, potency, and low toxicity of peptides make them attractive drug candidates. However, their rapid clearance, poor permeability, and potential instability can make them challenging to develop. Learn how recent advances in drug discovery and peptide engineering have led to significant progress in overcoming such challenges.
Whitepaper - Clinical and Formulation Strategies for Targeted Peptide Drug Development: Q&A with Dr. Andrew Lewis
Dr. Andrew Lewis, Chief Scientific Officer, examines how chemistry, manufacturing, and controls (CMC) and clinical strategies for peptide drugs can be further improved, answering questions on the challenges and potential solutions associated with development of injectable and oral peptide drugs.
Learn more about the benefits of working with us, our state-of-the-art global facilities in both the US and UK, and our core services, including drug product development & manufacturing, Translational Pharmaceutics®, and clinical pharmacology.
